ADAR1 Capital Management LLC Purchases 175,000 Shares of Pfizer Inc. $PFE

ADAR1 Capital Management LLC raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 226.1% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 252,400 shares of the biopharmaceutical company's stock after acquiring an additional 175,000 shares during the period. ADAR1 Capital Management LLC's holdings in Pfizer were worth $6,078,000 as of its most recent filing with the SEC.

Get Pfizer SMS alerts:

Sign Up

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. raised its holdings in shares of Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock worth $12,754,464,000 after acquiring an additional 31,412,883 shares during the last quarter. State Street Corp raised its stake in shares of Pfizer by 0.5% in the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company's stock worth $7,481,085,000 after purchasing an additional 1,357,756 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Pfizer by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company's stock valued at $3,235,642,000 after purchasing an additional 1,184,728 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company's stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $1,830,986,000. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 2.0%

Shares of Pfizer stock opened at $28.53 on Wednesday. The firm has a market cap of $162.60 billion, a PE ratio of 37.54 and a beta of 0.34. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The stock has a fifty day moving average price of $25.39 and a 200-day moving average price of $26.27.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the firm earned $0.78 EPS. The firm's quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.0%. Pfizer's dividend payout ratio (DPR) is presently 226.32%.

Analysts Set New Price Targets

PFE has been the subject of a number of analyst reports. BMO Capital Markets lowered their price target on Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday, July 13th. Weiss Ratings downgraded shares of Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a report on Monday, August 17th. UBS Group reiterated a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. Royal Bank Of Canada upgraded shares of Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 target price for the company in a report on Tuesday, June 9th. Finally, HSBC lowered shares of Pfizer from a "buy" rating to a "hold" rating and dropped their price target for the company from $32.00 to $28.00 in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $28.28.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source